Association between toll-like receptor 4 expression and symptoms of major depressive disorder

Código QR

Association between toll-like receptor 4 expression and symptoms of major depressive disorder

Ming-Kung Wu,1 Tiao-Lai Huang,1,2 Kai-Wei Huang,3 Ya-Ling Huang,1 Yi-Yung Hung1,4 1Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 2Genomic and Proteomic Core Laboratory, Department of Medical Research, Kaohsiung Chang Gung Memorial Ho...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wu MK, Huang TL, Huang KW, Huang YL, Hung YY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/b2c7c505878e482ab1222f7ab07aaa1a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
por: Singh M, et al.
Publicado: (2012)

Anatomical and functional brain abnormalities in unmedicated major depressive disorder
por: Yang X, et al.
Publicado: (2015)

Desvenlafaxine in the treatment of major depressive disorder
por: Maria Teresa C Lourenco1, et al.
Publicado: (2009)

The predictive value of somatic and cognitive depressive symptoms for cytokine changes in patients with major depression
por: Dannehl K, et al.
Publicado: (2014)

Psychiatric comorbidities in patients with major depressive disorder
por: Thaipisuttikul P, et al.
Publicado: (2014)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Mazen K Ali, et al.
Publicado: (2011)

Augmentation treatment in major depressive disorder: focus on aripiprazole
por: J Craig Nelson, et al.
Publicado: (2008)

Mitochondrial dysfunction, oxidative stress, and major depressive disorder
por: Tobe EH
Publicado: (2013)

Levomilnacipran for the treatment of major depressive disorder: a review
por: Asnis GA, et al.
Publicado: (2015)

Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder
por: Jha MK, et al.
Publicado: (2017)

Major depressive disorder: mechanism-based prescribing for personalized medicine
por: Saltiel PF, et al.
Publicado: (2015)

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
por: Zhang XF, et al.
Publicado: (2015)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez E, et al.
Publicado: (2014)

Electroconvulsive therapy treatment in patients with somatic symptom and related disorders
por: Leong KW, et al.
Publicado: (2015)

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
por: Bernhard T Baune
Publicado: (2008)

Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
por: Aoki A, et al.
Publicado: (2014)

Sex differences in gut microbiota in patients with major depressive disorder
por: Chen JJ, et al.
Publicado: (2018)

Major depressive disorders in chronic hemodialysis patients in Nazareth: identification and assessment
por: Armaly Z, et al.
Publicado: (2012)

Getting the balance right: Established and emerging therapies for major depressive disorders
por: Bojana Perovic, et al.
Publicado: (2010)

Comparison of duloxetine and SSRI as a treatment option of painful physical symptoms associated with major depressive disorder
por: Haider M, et al.
Publicado: (2017)

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
por: Marty Hinz, et al.
Publicado: (2010)

Evaluating depressive symptoms in mania: a naturalistic study of patients with bipolar disorder
por: Young AH, et al.
Publicado: (2015)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
por: Huang Q, et al.
Publicado: (2016)

A review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder
por: Baskaran A, et al.
Publicado: (2013)

Prevalence and diagnostic distribution of medically unexplained painful somatic symptoms across 571 major depressed outpatients
por: Fornaro M, et al.
Publicado: (2011)

Neutrophil–lymphocyte ratio in patients with major depressive disorder undergoing no pharmacological therapy
por: Demir S, et al.
Publicado: (2015)

Residual symptoms in patients with partial versus complete remission of a major depressive disorder episode: patterns of painful physical symptoms in depression
por: Harada E, et al.
Publicado: (2016)

The impact of the duration of an untreated episode on improvement of depression and somatic symptoms
por: Hung CI, et al.
Publicado: (2015)

Noradrenergic symptom cluster in depression
por: Montgomery S, et al.
Publicado: (2011)

Frequency and risk factor analysis of cognitive and anxiety-depressive disorders in patients with amyotrophic lateral sclerosis/motor neuron disease
por: Cui F, et al.
Publicado: (2015)

Psychometric Properties of the Chinese Version of the Clinically Useful Depression Outcome Scale for Patients with Major Depressive Disorder
por: Ma HY, et al.
Publicado: (2021)

Relationship of Subjective Cognitive Impairment with Psychosocial Function and Relapse of Depressive Symptoms in Patients with Major Depressive Disorder: Analysis of Longitudinal Data from PERFORM-J
por: Sumiyoshi T, et al.
Publicado: (2021)

Modulatory interactions of resting-state brain functional connectivity in major depressive disorder
por: Tu Z, et al.
Publicado: (2018)

Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
por: Kitaichi Y, et al.
Publicado: (2013)

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
por: Berman R, et al.
Publicado: (2011)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
por: Thase ME, et al.
Publicado: (2018)

The Relationship Between Baseline Clinical Symptom Characteristics and Working Ability in Japanese Patients Treated for Major Depressive Disorder and Painful Physical Symptoms
por: Sugawara N, et al.
Publicado: (2020)

An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis
por: Kuga A, et al.
Publicado: (2017)

Age-associated decrease in global DNA methylation in patients with major depression
por: Tseng PT, et al.
Publicado: (2014)

Predisposition for borderline personality disorder with comorbid major depression is associated with that for polycystic ovary syndrome in female Japanese population
por: Kawamura S,&nbsp;Maesawa C,&nbsp;Nakamura K,&nbsp;Nakayama K,&nbsp;Morita M,&nbsp;Hiruma Y,&nbsp;Yoshida T,&nbsp;Sakai A,&nbsp;Masuda T
Publicado: (2011)